Table 2.
Treatment at 5-year follow-up
| Total population (N = 207)a | Targeted therapy (N = 102) | Conventional therapy (N = 105) | P-value | |
|---|---|---|---|---|
| MRA | 86 (42%) | 76 (75%) | 10 (9%) | <0.001 |
| Spironolactone (mg) | 25 (12–50) | 38 (25–50) | 12 (12–25) | 0.130 |
| Eplerenon (mg) | 50 (25–50) | 50 (25–50) | 25 (25–25) | 0.062 |
| Statin | 140 (68%) | 82 (80%) | 58 (55%) | <0.001 |
| Simvastatin (mg) | 40 (20–40) | 40 (20–40) | 40 (40–40) | 0.724 |
| Rosuvastatin (mg) | 10 (8–10) | 10 (5–10) | 10 (10–10) | 0.095 |
| ACE-inhibitor and/or ARB | 159 (76%) | 80 (78%) | 79 (75%) | 0.624 |
| Enalapril (mg) | 20 (9–20) | 12 (5–20) | 20 (18–20) | 0.405 |
| Perindopril (mg) | 4 (2–8) | 3 (2–6) | 4 (4–8) | 0.062 |
| Losartan (mg) | 75 (50–100) | 50 (50–100) | 100 (50–100) | 0.384 |
| Telmisartan (mg) | 40 (40–80) | 40 (30–80) | 80 (40–80) | 0.408 |
| Physical activity during follow-up | 146 (71%) | 73 (72%) | 73 (70%) | 0.763 |
| Duration >150 min/weekb | 118 (57%) | 58 (57%) | 60 (57%) | 1.000 |
Data are presented as number of patients (%) or median (IQR).
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist.
a
Data are excluding eight patients that died during LTF and one patient lost to follow-up.
b
International physical activity norm.